SCHEMBL24009456

SCHEMBL24009456

Cc1cc2c(-c3ccc(Cl)cc3F)nc(N3CCO[C@@H](c4cn[nH]c4)C3)cc2nc1C

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 4/20 0.36
▸ EIF2AK4 Q9P2K8 5/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ GSK3B P49841 4/20 0.32
▸ PDE2A O00408 2/20 0.32
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ PIK3CB P42338 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ PKM P14618 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ PRCP P42785 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24010404 0.87 P2RX7 (0.35) PDE10AMEN1NPC1RAB9AKMT2A
SCHEMBL30160504 0.87 P2RX7 (0.35) PDE10AMEN1NPC1RAB9AKMT2A
SCHEMBL24010825 0.87 P2RX7 (0.35) PDE10AMEN1NPC1RAB9AKMT2A
SCHEMBL24010865 0.87 P2RX7 (0.35) PDE10AMEN1NPC1RAB9AKMT2A
SCHEMBL24010700 0.85 PDE10A (0.37) PDE10AEIF2AK4GSK3BPDE2ACYP1A2
SCHEMBL30160457 0.85 PDE10A (0.37) PDE10AEIF2AK4MEN1NPC1RAB9A
SCHEMBL24009481 0.85 PDE10A (0.37) PDE10AEIF2AK4MEN1NPC1RAB9A
SCHEMBL24001803 0.82 GSK3B (0.37) PDE10AEIF2AK4GSK3BPDE2ACYP1A2
SCHEMBL24002174 0.82 GSK3B (0.37) PDE10AEIF2AK4GSK3BPDE2ACYP1A2
SCHEMBL24002175 0.82 GSK3B (0.37) PDE10AEIF2AK4GSK3BPDE2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021226629-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE AMGEN INC. (US) 2021-11-11 — — WO disclosed
Send feedback